Price Crosses Moving Average
|Bid||37.50 x 3200|
|Ask||37.59 x 4000|
|Day's Range||37.45 - 37.87|
|52 Week Range||27.88 - 44.56|
|Beta (5Y Monthly)||0.71|
|PE Ratio (TTM)||13.39|
|Earnings Date||Jul 27, 2020 - Jul 31, 2020|
|Forward Dividend & Yield||1.52 (4.05%)|
|Ex-Dividend Date||May 07, 2020|
|1y Target Est||41.36|
Novavax announced it would begin human trials for its coronavirus vaccine, while COVID-19 engulfs Brazil.
Biotech firm Novavax has entered its coronavirus vaccine in a Phase 1 clinical trial in Australia — the first in the Southern Hemisphere.
The coronavirus is taking a toll on mental health. The number of prescriptions for antidepressant, anti-anxiety and anti-insomnia medications filled per week increased 21% between Feb. 16 and March 15, 2020, according to a recent report by Express Scripts, a Cigna-owned (CI) pharmacy benefit manager. The study analyzed prescription claims filled between Jan. 19 and March 15 of this year among a sample of more than 31.5 million commercially-insured individuals, and found that claims peaked during the week ending March 15, when the novel coronavirus that causes COVID-19 was declared a pandemic.
As several pharma/biotech companies speed up efforts to make a vaccine for COVID-19, Novavax (NVAX) begins human testing of its candidate, NVX-CoV2373.
Pfizer stock could see some gains in 2020 if it makes progress on a coronavirus vaccine with BioNTech. But its Upjohn merger with Mylan is now delayed. Is Pfizer stock a buy now?
AbbVie stock recently broke out and the pharmaceutical company just wrapped its acquisition of Allergan. Is AbbVie stock a buy now?
In this article we will check out the progression of hedge fund sentiment towards Pfizer Inc. (NYSE:PFE) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 […]
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline
ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced that Pfizer Inc. (PFE) has entered into a stock purchase agreement with ContraFect pursuant to which Pfizer Inc. has agreed to purchase 674,156 shares of ContraFect’s common stock and a warrant to purchase 505,617 shares of ContraFect’s common stock, for approximately $3.0 million in a private placement transaction that is expected to close on May 27, 2020. The private placement is contingent upon the closing of ContraFect’s public offering previously announced on May 21, 2020, and there can be no assurance as to whether or when the private placement may be completed.
Vaccines are perceived as key to ending the restraints on work and life that have decimated the global economy, and returning to some sense of normalcy.
Abbott Labs (NYSE: ABT) made headlines in late March when the FDA gave emergency use authorization (EUA) for the company's COVID-19 test that runs on its ID NOW platform. Abbott also announced interim results last week from a clinical study in urgent care clinics that showed high levels of sensitivity for positive results and specificity for negative results.
The coronavirus pandemic accelerated a wellness renaissance among consumers as shelter in place orders took effect, based on some of the sales trends seen by companies including Ro.
Pfizer Inc. (NYSE: PFE) today announced that it and Wyeth recommend rejection of the unsolicited tender offer made by Huguenot Bond Liquidity, LLC ("Offeror") on May 11, 2020 (as amended and restated on May 21, 2020) to purchase up to $162.5 million principal amount of Pfizer’s outstanding 7.200% notes due 2039 (the "Pfizer Notes") and up to $130.0 million principal amount of Wyeth’s 5.950% notes due 2037 (the "Wyeth Notes" and together with the Pfizer Notes, the "Notes"). Wyeth is a wholly-owned subsidiary of Pfizer. Pfizer and Wyeth do not endorse Offeror’s unsolicited tender offer, and neither Pfizer nor Wyeth is affiliated or associated with the Offeror, the tender offer or the offer documentation. The Offeror did not inform Pfizer of the tender offer, and Pfizer only became aware of the offer through a third party source. Further, there is no disclosure of information regarding the Offeror or any indication as to a source of financing for the offer in the offer documentation.
CanSino Biologics, a Chinese vaccine company, announced on Friday that it saw strong, positive results from its phase one trials of a coronavirus vaccine, which it tested on 108 volunteers. Yahoo Finance’s Anjalee Khemlani joins The Final Round to break down the latest news about the coronavirus.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Yahoo Finance’s Brian Sozzi, Alexis Christoforous, and Anjalee Khemlani discuss the latest coronavirus news and the race for a vaccine.
Telehealth companies enabling individuals to see physicians without stepping foot into a physical doctor’s office are having their moment, as the coronavirus pandemic confines individuals and would-be patients across the country largely to their homes.
Many countries are cautiously emerging from lockdown but life may not completely return to normal until a coronavirus vaccine is found.
FDA approves line extensions for Bristol-Myers (BMY), Roche (RHHBY) and AstraZeneca (AZN)/Merck's (MRK) drugs. J&J stops sales of talc-based baby powders in the United States and Canada.
Biotech companies and drugmakers are speeding up development of a vaccine for COVID-19. This has seen many big players joining forces to come up with a treatment.
Vanderbilt University School of Medicine,Professor of Medicine in the Division of Infectious Diseases Dr. William Schaffner joins Yahoo Finance’s Seana Smith to discuss the coronavirus, as a quarter of Americans say they are nervous about a vaccine, according to a new Reuters/Ipsos poll.
Moderna’s development of a successful Sars-Cov-2 vaccine would validate the company’s technology and expand its platform, says Piper Sandler analyst Ted Tenthoff.